GlassScriptPhysician profile
James Low Jr
NPI 1083616403
$6,388.15
in general payments reported to CMS, 2019-2025
34 companies · $787 in 2025
The $787 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $681 · 2021: $1,197 · 2022: $856 · 2023: $825 · 2024: $1,139 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565 · Education: $170 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.84 |
| Education | $169.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $599.57 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.84 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $526.74 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $521.35 | 2021-2025 | |
| Harmony Biosciences LLC | $480.08 | 2023-2025 | Wakix |
| Glaxosmithkline, LLC. | $463.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $431.10 | 2019-2024 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $269.44 | 2019-2022 | |
| Novo Nordisk INC | $242.44 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.49 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $233.35 | 2019-2021 | |
| Medicure Pharma INC. | $149.72 | 2020-2024 | Zypitamag |
| Abbvie INC. | $106.81 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $105.36 | 2020-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $79.99 | 2021 | |
| Eisai INC. | $76.88 | 2020-2024 | |
| Idorsia Pharmaceuticals US INC | $71.72 | 2022-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $70.10 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.45 | 2022 | |
| Mylan Specialty L.P. | $47.42 | 2021-2023 | Yupelri |
| Corcept Therapeutics | $46.46 | 2024 | Korlym |
| Teva Pharmaceuticals USA, INC. | $45.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $44.23 | 2020-2023 | Eliquis |
| Abbott Laboratories | $31.44 | 2021-2024 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $29.18 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.09 | 2025 | Rexulti |
| Shield Therapeutics INC | $23.02 | 2024 | |
| Boston Scientific Corporation | $21.16 | 2023 | Watchman Access System |
| Medtronic Minimed, INC. | $19.96 | 2019 | |
| Melinta Therapeutics, LLC | $19.53 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.25 | 2024 | Nuzyra |
| Amarin Pharma, INC. | $11.39 | 2021 | |
| Allergan, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Low Jr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.